Nordic countries have had some of the highest rates of biosimilar use, and extensive registry data in these countries also allow for observational studies of biosimilar use in real-world clinical practice. A new study used data from 5 such registries—which included more than 2000 patients with spondyloarthritis—to assess retention rates for those treated with biosimilars or reference products of etanercept and infliximab.
Nordic countries have had some of the highest rates of biosimilar use, and extensive registry data in these countries also allow for observational studies of biosimilar use in real-world clinical practice. A new paper, published in RMD Open, used data from 5 such registries—which included more than 2000 patients with spondyloarthritis—to assess retention rates for those treated with biosimilars or reference products of etanercept and infliximab.
In the study, biologic-naïve patients with spondyloarthritis in the 5 Nordic nations who started treatment with reference etanercept (Enbrel), reference infliximab (Remicade), biosimilar etanercept (Benepali), or biosimilar infliximab (Remsima) between 2014 and 2017 were included. Data were derived from national biologics registers in Sweden (ARTIS), Denmark (DANBIO), Finland (ROB-FIN), and Iceland (ICEBIO), as well as the regional biologics register in Norway (NOR-DMARD).
In total, 2334 patients were included; 1319 patients received infliximab (24% reference, 76% biosimilar), and 1015 patients received etanercept (49% reference, 51% biosimilar). Apart from higher concomitant disease-modifying antirheumatic drug use in the reference cohorts, there were no clinically relevant differences in baseline characteristics among the patients who started therapy with reference drugs versus biosimilars.
The investigators found that retention among patient receiving reference and biosimilar drugs was similar at 1 year:
Two-year data were available for infliximab, and also showed similar retention:
Proportional hazard analyses showed a 5% decrease in risk of discontinuation favoring biosimilar infliximab over the reference, and a 15% decrease for biosimilar etanercept over its reference; however, the 95% CIs did not show a statistically significant decrease in risk.
While the study was limited by the fact that it did not allow for a direct comparison of efficacy, and the fact that not all countries contributed to all treatment arms due to biosimilar availability, “a strength of the present study is that confounders, such as nocebo related to the context of switching from a stable ongoing treatment with an originator to its (cheaper) biosimilar, should be minimized in a bionaïve population. Another strength is that the pooling of data from the different countries ought to reduce the risk of country-specific channeling towards originators or biosimilars,” write the authors.
Reference
Lindström U, Glintborg B, Di Giuseppe D, et al. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. RMD Open 2019;5:e001079. doi: 10.1136/rmdopen-2019-001079.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.